MTARC2
Mitochondrial amidoxime reducing component 2
Also known as: FLJ20605, MARC2, MARC2_HUMAN, MOSC2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q969Z3
- Gene
- MTARC2
- Ensembl
- ENSG00000117791
- Chromosome
- 1
- Canonical length
- 335 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
The protein encoded by this gene is an enzyme found in the outer mitochondrial membrane that reduces N-hydroxylated substrates. The encoded protein uses molybdenum as a cofactor and cytochrome b5 type B and NADH cytochrome b5 reductase as accessory proteins. One type of substrate used is N-hydroxylated nucleotide base analogues, which can be toxic to a cell. Other substrates include N(omega)-hydroxy-L-arginine (NOHA) and amidoxime prodrugs, which are activated by the encoded enzyme. Multiple transcript variants encoding the different isoforms have been found for this gene. [provided by RefSeq, Sep 2016]
Canonical amino-acid sequenceUniProt
335 residues, UniProt reviewed canonical sequence.
>Q969Z3|MTARC2
1 MGASSSSALA RLGLPARPWP RWLGVAALGL AAVALGTVAW RRAWPRRRRR LQQVGTVAKL
61 WIYPVKSCKG VPVSEAECTA MGLRSGNLRD RFWLVIKEDG HMVTARQEPR LVLISIIYEN
121 NCLIFRAPDM DQLVLPSKQP SSNKLHNCRI FGLDIKGRDC GNEAAKWFTN FLKTEAYRLV
181 QFETNMKGRT SRKLLPTLDQ NFQVAYPDYC PLLIMTDASL VDLNTRMEKK MKMENFRPNI
241 VVTGCDAFEE DTWDELLIGS VEVKKVMACP RCILTTVDPD TGVIDRKQPL DTLKSYRLCD
301 PSERELYKLS PLFGIYYSVE KIGSLRVGDP VYRMVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MTARC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 209 nTPM
Expression across tissuesHPA
Tissue
- liver: 209 nTPM
- kidney: 123 nTPM
- parathyroid gland: 117 nTPM
- choroid plexus: 83 nTPM
- duodenum: 56 nTPM
- small intestine: 55 nTPM
Single-cell type
- choroid plexus epithelial cells: 267 nCPM
- proximal tubule cells: 228 nCPM
- hepatocytes: 155 nCPM
- sertoli cells: 131 nCPM
- enterocytes: 115 nCPM
- pituitary stem cells: 103 nCPM
Immune cell
- basophil: 14 nTPM
- memory B-cell: 2.2 nTPM
- naive B-cell: 0.9 nTPM
- classical monocyte: 0.1 nTPM
- total PBMC: 0.1 nTPM
- eosinophil: 0 nTPM
Brain region
- choroid plexus: 109 nTPM
- cerebral cortex: 21 nTPM
- thalamus: 20 nTPM
- midbrain: 20 nTPM
- basal ganglia: 19 nTPM
- hippocampal formation: 18 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular detoxification of nitrogen compound
- detoxification of nitrogen compound
- nitrate metabolic process
- nitric oxide biosynthetic process
Molecular functions
- molybdenum ion binding
- molybdopterin cofactor binding
- nitrate reductase activity
- nitrite reductase activity
- oxidoreductase activity, acting on other nitrogenous compounds as donors
- pyridoxal phosphate binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MTARC2 as an antibody target. Whether an autoantibody or antibody against MTARC2 could matter depends on whether native MTARC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MTARC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MTARC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...